LOXITANE (loxapine succinate) by Teva is clinical pharmacology pharmacodynamics pharmacologically, loxapine is an antipsychotic for which the exact mode of action has not been established. Approved for schizophrenia, comatose, severe drug-induced depressed states (alcohol and 3 more indications. First approved in 1975.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
LOXITANE (loxapine succinate) is a first-generation antipsychotic oral tablet approved in 1975 for schizophrenia and severe drug-induced depressed states. The drug works by modulating subcortical inhibitory areas, producing sedation within 20-30 minutes and suppressing aggressive behavior, though its exact mechanism remains incompletely understood. Loxapine is rapidly absorbed, extensively metabolized, and excreted primarily within 24 hours.
As a legacy antipsychotic approaching loss of exclusivity, LOXITANE faces declining commercial opportunity with minimal team expansion and focus on cost management rather than growth initiatives.
CLINICAL PHARMACOLOGY Pharmacodynamics Pharmacologically, loxapine is an antipsychotic for which the exact mode of action has not been established. However, changes in the level of excitability of subcortical inhibitory areas have been observed in several animal species in association with such…
Worked on LOXITANE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on LOXITANE offers limited career growth due to its LOE-approaching status and saturated generic market, with roles concentrated in cost management and regulatory compliance rather than innovation or market expansion. Professionals joining this product should expect stable but non-growth-oriented responsibilities focused on defending market position against generics and managing legacy asset performance.